Issue

Vol. 66 No. 7: Issue 7

The undersigned hereby assign all rights, included but not limited to copyright, for this manuscript to CMB Association upon its submission for consideration to publication on Cellular and Molecular Biology. The rights assigned include, but are not limited to, the sole and exclusive rights to license, sell, subsequently assign, derive, distribute, display and reproduce this manuscript, in whole or in part, in any format, electronic or otherwise, including those in existence at the time this agreement was signed. The authors hereby warrant that they have not granted or assigned, and shall not grant or assign, the aforementioned rights to any other person, firm, organization, or other entity. All rights are automatically restored to authors if this manuscript is not accepted for publication.

Development of poly ADP-ribose polymerase-1 inhibitor with anti-cervical carcinoma activity

https://doi.org/10.14715/cmb/2020.66.7.6
Tong-Mei Zhang
Department of Obstetrics and Gynecology, Baoji Maternal and Child Health Hospital, Baoji Shaanxi, 721000
Wen Wang
Department of Pathology, Shangluo Central Hospital, Shangluo Shaanxi, 726000

Corresponding Author(s) : Wen Wang

wenwang0207@163.com

Cellular and Molecular Biology, Vol. 66 No. 7: Issue 7

Abstract

This research aimed to discover and identify new poly ADP-ribose polymerase-1 (PARP) inhibitors with potent anti-cervical carcinoma activity, and then explore their potential biological roles on cervical carcinoma cell. For this purpose, we identified a new PARP inhibitor from a high-throughput virtual screening method and found that the compound strongly inhibited cervical carcinoma HeLa cell. Cell proliferation was evaluated by an MTT assay, and the cell apoptosis was assessed by flow cytometry. Results showed that PARP1 is a poly ADP-ribose catalyzing enzyme in eukaryotic cells, which is activated during DNA damage and repair, and plays an important role in DNA repair and cell apoptosis. Herein we report the first discovery of a new PARP inhibitor from a high-throughput virtual screening method, then the compound was measured its anti-cervical carcinoma activity by using an MTT assay, which suggested that the compound strongly inhibited HeLa cell proliferation, the IC50 value is 0.65 µM. In addition, the compound induced HeLa cell apoptosis in a dose-response manner. All these data suggested that the compound is a promising lead compound, which deserves further investigation. It is concluded that the compound discover herein is a promising PARP-1 inhibitor with potent anti-cervical carcinoma activity, which deserves further investigation.

Keywords

Cervical carcinoma PARP inhibitor Proliferation Apoptosis
Zhang, T.-M., & Wang, W. (2020). Development of poly ADP-ribose polymerase-1 inhibitor with anti-cervical carcinoma activity. Cellular and Molecular Biology, 66(7), 31–34. https://doi.org/10.14715/cmb/2020.66.7.6
Download Citation
Endnote/Zotero/Mendeley (RIS)
BibTeX
References
  1. Moore DH, Tian C, Monk BJ, et al. Prognostic factors for response to cisplatin based chemotherapy in advanced cervical carcinoma: A Gynecologic Oncology Group Study. Gynecol Oncol, 2010; 116: 44-49.
  2. Kitagawa R, Katsumata N, Shibata T, et al. Paclitaxel plus carboplatin versus paclitaxel plus cisplatin in metastatic or recurrent cervical cancer: The open-label randomized phase â…¢ trial JCOG0505. J Clin Oncol 2015; 33: 2129-2135
  3. Kumar L, Gupta S. Integrating chemotherapy in the management of cervix cancer-a critical appraisal. Oncol 2016; 91: 8-12.
  4. Loizzi V, Cormio G, Vicino M, et al. Neoadjuvant Chemotherapy: An alternative option of treatment for locally advanced cervical cancer. Gynecol Obstet Invest; 2008, 65: 96-103.
  5. Singh RB, Chandra S, Mohanti BK, et al. Neoadjuvant chemotherapy with weekly paclitaxel and carboplatin followed by chemoradiation in locally advanced cervical carcinoma: A pilot study. Gynecol Oncol 2013; 129: 124-128.
  6. D'Amours D, Desnoyers S, D'Silva I, et al. Poly (ADP-ribosyl)ation reactions in the regulation of nuclear functions. Biochem J, 1999, 342: 249–268.
  7. Miwa M, Matsutani M. PolyADP-ribosylation and cancer. Cancer Sci 2007; 98: 1528-1535.
  8. Dantzer F, de La Rubia G, Ménissier-De Murcia J, et al. Base excision repair is impaired in mammalian cells lacking poly(ADP-ribose)polymerase-1. Biochemistry 2000; 39: 7559-7569.
  9. Soldatenkov VA, Smulson M. Poly(ADP-ribose) polymerase in DNA damage response pathway: implications for radiation oncology. Int J Cancer 2000; 90 (2): 59–67.
  10. Bryant HE, Schultz N, Thomas HD, et al. Specific killing of BRCA2-deficient tumors with inhibitors of poly(ADP-ribose) polymerase. Nature 2005; 434: 913-917.
  11. McCabe N, Turner NC, Lord CJ, et al. Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibition. Cancer Res 2006; 66: 8109–8115.
  12. Tentori L, Portarena I, Graziani G. Potential clinical application of poly(ADP-ribose) polymerase inhibition. Pharmacol Res 2002; 5: 73-85.
  13. Rouleau M, Patel A, Hendzel MJ, et al. PARP inhibition PARP1 and beyond. Nat Rev Cancer 2010; 10: 293-301.
  14. Vinod KR, Chandra S, Sharma SK. Evaluation of 5-aminoisoquinoline (5-AIQ), a novel PARP-1 inhibitor for genotoxicity potential in vitro and in vivo. Toxicol Mech Methods 2010; 20: 90-95.
  15. Ferraris DV. Evolution of poly(ADP-ribose) polymerase-1 (PARP-1) inhibitors. From concept to clinic. J. Med. Chem 2010; 53: 4561-4584.
  16. He JX, Yang CH, Miao ZH. Poly(ADP-ribose) polymerase inhibitors as promising cancer therapeutics. Acta Pharmacol. Sin 2010; 31: 1172-1180.
  17. Menear KA, Adcock C, Boulter R, et al. 4-[3-(4-cyclopropanecarbonylpiperazine-1-carbonyl)-4- fluorobenzyl]-2 Hphthalazin-1-one: a novel bioavailable inhibitor of poly (ADP-ribose) polymerase-1. J Med Chem 2008; 51: 6581-6591.
  18. Patel AG, De Lorenzo SB, Flatten KS, et al. Failure of iniparib to inhibit poly(ADP-Ribose) polymerase in vitro. Clin Cancer Res 2012; 18: 1655-1662.
  19. Jones P, Wilcoxen K, Rowley M, et al. Niraparib: A Poly(ADP-ribose) polymerase (PARP) inhibitor for the treatment of tumors with defective homologous recombination. J Med Chem 2015; 58: 3302-3314.
  20. Murai J, Huang SY, Das BB, et al. Trapping of PARP1 and PARP-2 by clinical PARP inhibitors. Cancer Res 2012; 72: 5588-5599.
  21. Rodriguez MI, Majuelos-Melguizo J, Martí­ Martí­n-Consuegra JM, et al. Deciphering the insights of poly(ADP-ribosylation) in tumor progression. Med Res Rev 2015; 35: 678−697.
  22. Ihnen M, Eulenburg C, Kolarova T, et al. Therapeutic potential of the poly(ADP-ribose) polymerase inhibitor rucaparib for the treatment of sporadic human ovarian cancer. Mol Cancer Ther 2013; 12: 1002-1015.
  23. Vilar E, Bartnik CM, Stenzel SL, et al. MRE11 deficiency increases sensitivity to poly(ADPribose) polymerase inhibition in microsatellite unstable colorectal cancers. Cancer Res 2011; 71: 2632-2642.
  24. Joshi PM, Sutor SL, Huntoon CJ, et al. Ovarian cancer-associated mutations disable catalytic activity of CDK12, a kinase that promotes homologous recombination repair and resistance to cisplatin and poly(ADP-ribose) polymerase inhibitors. J Biol Chem 2014; 289: 9247-9253.
Read More
Author biographies is not available.
Crossref
Scopus
Google Scholar
Europe PMC
Download this PDF file
PDF
Statistic
Read Counter : 853 Download : 467